NXP800 yields neither severe thrombocytopenia, nor any responses.
ApexOnco Front Page
Recent articles
For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
Imfinzi scores an unexpected approval based on a post-hoc subgroup analysis.
More details on cardiovascular events with the group’s anti-CD47 project comforted analysts, but shares still fell 10%.
$100m buys an option over another third-gen drug, but Scemblix casts a long shadow.
Combination efficacy looks similar to Kura’s, but adverse events with revumenib could raise concerns again.
Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.
The group's enthusiasm is backed by an academic trial of INB-100 in 10 AML patients.
